SCHEMBL29357948

SCHEMBL29357948

CSc1ncc2nc(-c3ccc(NS(=O)(=O)Cc4ccccc4)c(F)c3)c(=O)n(C(C)C)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 7/20 0.56
CYP1A2 P05177 7/20 0.40
USP2 O75604 6/20 0.40
CYP3A4 P08684 4/20 0.40
CYP2C9 P11712 4/20 0.40
CYP2C19 P33261 4/20 0.40
MAPK1 P28482 3/20 0.40
MAPT P10636 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
JAK1 P23458 1/20 0.37
HSD17B10 Q99714 5/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 4/20 0.36
CASP1 P29466 4/20 0.36
CASP7 P55210 4/20 0.36
HIF1A Q16665 3/20 0.36
LMNA P02545 2/20 0.36
RECQL P46063 2/20 0.36
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190959 1.00 ERN1 (0.56) ERN1CYP1A2USP2CYP3A4CYP2C9
SCHEMBL25035369 0.89 ERN1 (0.57) ERN1CYP1A2USP2CYP3A4CYP2C9
SCHEMBL29356032 0.89 ERN1 (0.56) ERN1CYP1A2USP2CYP3A4CYP2C9
SCHEMBL22190877 0.89 ERN1 (0.56) ERN1CYP1A2USP2CYP3A4CYP2C9
SCHEMBL22200711 0.85 ERN1 (0.41) ERN1CYP1A2USP2CYP3A4CYP2C9
SCHEMBL22190905 0.85 ERN1 (0.49) ERN1CYP1A2USP2CYP3A4CYP2C19
SCHEMBL29356732 0.85 ERN1 (0.49) ERN1CYP1A2USP2CYP3A4CYP2C19
SCHEMBL22190651 0.85 ERN1 (0.58) ERN1CYP1A2USP2CYP3A4MAPT
SCHEMBL29353080 0.85 ERN1 (0.58) ERN1CYP1A2USP2CYP3A4MAPT
SCHEMBL25035335 0.83 ERN1 (0.58) ERN1CYP1A2USP2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3941919-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES Genentech, Inc. (US) 2022-01-26 EP disclosed